MAdCAM1 Protein, Human (HEK293, His)

MAdCAM1 is a cell adhesion leukocyte receptor expressed primarily by mucosal venules and plays a critical role in coordinating lymphocyte trafficking into mucosal tissues, particularly Peyer's patches and intestinal lamina propria. This protein exhibits the ability to bind integrins α-4/β-7 and L-selectin, thereby regulating the passage and retention of leukocytes in the mucosal environment. MAdCAM1 Protein, Human (HEK293, His) is the recombinant human-derived MAdCAM1 protein, expressed by HEK293 , with C-6*His labeled tag.

Mucosal Addressin Cell Adhesion Molecule 1 (MAdCAM1) is a cell adhesion leukocyte receptor expressed on the endothelial cells of mucosal venules, playing a crucial role in directing lymphocyte traffic into mucosal tissues, particularly the Peyer patches and the intestinal lamina propria. MAdCAM1 serves as a binding partner for both integrin alpha-4/beta-7 and L-selectin, thereby regulating the passage and retention of leukocytes in mucosal tissues. The homodimeric structure of MAdCAM1 contributes to its functional role in mediating adhesion between endothelial cells and circulating immune cells. Notably, isoform 2, which lacks the mucin-like domain, may have a specialized function in supporting integrin alpha-4/beta-7-dependent adhesion strengthening, independent of L-selectin binding. Understanding the features and interactions of MAdCAM1 provides insights into the intricate mechanisms governing lymphocyte trafficking in mucosal tissues.

1.Measured by the ability of the immobilized protein to support the adhesion of Jurkat human T-lymphocyte leukemia cells in the presence of 1 mM MnCl2. The ED₅₀ for this effect is 1.987 μg/mL, corresponding to a specific activity is 503.2 units/mg.
2.Measured by the ability of the immobilized protein to support the adhesion of Jurkat human T-lymphocyte leukemia cells. When 5×10⁴ cells/well are added to Human MAdCAM-1 coated plates (2.5 μg/mL with 100 µL/well), approximately 52.575%-62.728% will adhere after 1 hour incubation at 37 °C in the presence of 1 mM MnCl₂.

• 
  Measured by the ability of the immobilized protein to support the adhesion of Jurkat human T-lymphocyte leukemia cells in the presence of 1 mM MnCl2. The ED₅₀ for this effect is 1.987 μg/mL, corresponding to a specific activity is 503.2 units/mg.

Human

HEK293

C-6*His

Q4PKD0 (Q19-Q333)

/

QSLQVKPLQVEPPEPVVAVALGASRQLTCRLACADRGASVQWRGLDTSLGAVQSDTGRSVLTVRNASLSAAGTRVCVGSCGGRTFQHTVQLLVYAFPDQLTVSPAALVPGDPEVACTAHKVTPVDPNALSFSLLVGGQELEGAQALGPEVQEEEEEPQGDEDVLFRVTERWRLPPLGTPVPPALYCQATMRLPGLELSHRQAIPVLHSPTSPEPPDTTSPESPDTTSPESPDTTSQEPPDTTSQEPPDTTSQEPPDTTSPEPPDKTSPEPAPQQGSTHTPRSPGSTRTRRPEISQAGHTQGKVIPTGSSKPAGDQ

Approximately 55-75 kDa due to the glycosylation.

• 
  Greater than 95% as determined by reducing SDS-PAGE.

Lyophilized powder

Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4 or PBS, pH 7.4, 5% trehalose, 5% mannitol and 0.01% Tween80 or PBS, pH 7.4, 8% trehalose.

<1 EU/μg, determined by LAL method.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).

Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US; may vary elsewhere.